| Field | Specification |
|---|---|
| Target | |
| Alternative names | Pyruvate kinase PKLR;2.7.1.40;Pyruvate kinase 1;Pyruvate kinase isozymes L/R;R-type/L-type pyruvate kinase;Red cell/liver pyruvate kinase;PKLR;PK1, PKL; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human PKLR, different from the related mouse sequence by one amino acid, and identical to the rat sequence. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes pyruvate kinase PKLR in human, mouse and rat samples and is validated for IHC and Western blot. The predicted molecular weight is 61.8 kDa, and the supplier reports an observed band at about 62 kDa.
PKLR encodes the liver and red blood cell isoforms of pyruvate kinase, which convert phosphoenolpyruvate to pyruvate and generate ATP in the last step of glycolysis. Mutations in PKLR cause pyruvate kinase deficiency, a common inherited cause of nonspherocytic hemolytic anemia.
| Target | Pyruvate kinase PKLR (gene PKLR; UniProt P30613, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 61.8 kDa |
| Observed MW | 62 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| IHC (paraffin sections) | 0.5–1 µg/mL (Human) |
|---|---|
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
Samples with a confirmed band (WB): human HepG2 cells, rat liver tissue, mouse liver tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human intestinal cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Synthetic peptide from the C-terminal region of human PKLR. It differs from the mouse sequence at one residue.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Ying Zhang et al. (2018) miR-1322 regulates ChREBP expression via binding a 3′-UTR variant (rs1051943). Journal of Cellular and Molecular Medicine. 10.1111/jcmm.13805
